All attempts to induce broadly neutralising antibodies such as mAb 2F5 and mAb 4E10 targeting conserved epitopes in the membrane proximal external region (MPER) of the transmembrane envelope (TM) protein gp41 of HIV-1 failed so far. In contrast, in previous studies, immunising with the ectodomain of the TM protein p15E of different gammaretroviruses, we successfully induced neutralising antibodies. These antibodies recognised epitopes located in the fusion peptide proximal region (FPPR) and in the MPER of p15E. The epitope in the MPER of p15E corresponds to that of the mAb 4E10 in gp41 in terms of location within the protein and partial sequence homology. In order to present the MPER of gp41 (containing the 2F5 and 4E10 epitopes) membrane-a...
SummaryBroadly neutralizing monoclonal antibodies to HIV-1 are rare but invaluable for vaccine desig...
The broadly neutralizing human monoclonal antibodies (MAbs) 2F5 and 4E10, both targeting the highly ...
Abstract A human immunodeficiency virus type-1 (HIV-1) vaccine which is able to effectively prevent ...
All attempts to induce broadly neutralising antibodies such as mAb 2F5 and mAb 4E10 targeting conser...
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by exper...
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by exper...
AbstractThe membrane-proximal external region (MPER) of gp41 is considered as a prime target for the...
Although the development of an effective vaccine is the main goal in the fight against AIDS, all att...
The membrane proximal external region (MPER) of the HIV-1 glycoprotein gp41 is targeted by the broad...
The membrane proximal external region (MPER) of the HIV-1 glycoprotein gp41 is targeted by the broad...
The production of broadly neutralizing antibodies (bNAbs) is a major goal in the development of an H...
The induction of 2F5- and 4E10-like antibodies broadly neutralising HIV-1 and targeting the membrane...
Although human immunodeficiency type 1 (HIV-1) infection induces strong antibody responses to the vi...
AbstractThe membrane-proximal external region (MPER) of HIV-1 gp41 is an attractive target for vacci...
Although human immunodeficiency type 1 (HIV-1) infection induces strong antibody responses to the vi...
SummaryBroadly neutralizing monoclonal antibodies to HIV-1 are rare but invaluable for vaccine desig...
The broadly neutralizing human monoclonal antibodies (MAbs) 2F5 and 4E10, both targeting the highly ...
Abstract A human immunodeficiency virus type-1 (HIV-1) vaccine which is able to effectively prevent ...
All attempts to induce broadly neutralising antibodies such as mAb 2F5 and mAb 4E10 targeting conser...
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by exper...
Broadly neutralizing antibodies are not commonly produced in HIV-1 infected individuals nor by exper...
AbstractThe membrane-proximal external region (MPER) of gp41 is considered as a prime target for the...
Although the development of an effective vaccine is the main goal in the fight against AIDS, all att...
The membrane proximal external region (MPER) of the HIV-1 glycoprotein gp41 is targeted by the broad...
The membrane proximal external region (MPER) of the HIV-1 glycoprotein gp41 is targeted by the broad...
The production of broadly neutralizing antibodies (bNAbs) is a major goal in the development of an H...
The induction of 2F5- and 4E10-like antibodies broadly neutralising HIV-1 and targeting the membrane...
Although human immunodeficiency type 1 (HIV-1) infection induces strong antibody responses to the vi...
AbstractThe membrane-proximal external region (MPER) of HIV-1 gp41 is an attractive target for vacci...
Although human immunodeficiency type 1 (HIV-1) infection induces strong antibody responses to the vi...
SummaryBroadly neutralizing monoclonal antibodies to HIV-1 are rare but invaluable for vaccine desig...
The broadly neutralizing human monoclonal antibodies (MAbs) 2F5 and 4E10, both targeting the highly ...
Abstract A human immunodeficiency virus type-1 (HIV-1) vaccine which is able to effectively prevent ...